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A B S T R A C T
Purpose
To update guideline recommendations on the role of bone-modifying agents in multiple myeloma.
Methods
An update panel conducted a targeted systematic literature review by searching PubMed and the
Cochrane Library for randomized controlled trials, systematic reviews, meta-analyses, clinical
practice guidelines, and observational studies.
Results
Thirty-five relevant studies were identified, and updated evidence supports the current
recommendations.
Recommendations
For patients with active symptomatic multiple myeloma that requires systemic therapy with or
without evidence of lytic destruction of bone or compression fracture of the spine from osteopenia
on plain radiograph(s) or other imaging studies, intravenous administration of pamidronate 90 mg
over at least 2 hours or zoledronic acid 4 mg over at least 15 minutes every 3 to 4 weeks is
recommended. Denosumab has shown to be noninferior to zoledronic acid for the prevention of
skeletal-related events and provides an alternative. Fewer adverse events related to renal toxicity
have been noted with denosumab compared with zoledronic acid and may be preferred in this
setting. The update panel recommends that clinicians consider reducing the initial pamidronate dose
in patients with preexisting renal impairment. Zoledronic acid has not been studied in patients with
severe renal impairment and is not recommended in this setting. The update panel suggests that
bone-modifying treatment continue for up to 2 years. Less frequent dosing has been evaluated and
should be considered in patients with responsive or stable disease. Continuous use is at the
discretion of the treating physician and the risk of ongoing skeletal morbidity. Retreatment should be
initiated at the time of disease relapse. The update panel discusses measures regarding osteo-
necrosis of the jaw. Additional information is available at www.asco.org/hematologic-malignancies-
guidelines and www.asco.org/guidelineswiki.
J Clin Oncol 36:812-818. © 2018 by American Society of Clinical Oncology
INTRODUCTION
The goal of this update is to provide oncologists,
hematologists, other health care practitioners,
patients, and caregivers with recommendations
regarding the role of bone-modifying agents in
multiple myeloma.
ASCO first published evidence-based clinical
practice guidelines on the role of bisphosphonates in
multiple myeloma in 2002 and an update in 2007.1
The goal of this 2017 guideline update is to pro-
vide oncologists and other clinicians with current
recommendations regarding the role of bone-
modifying agents (BMAs) in multiple myeloma.
The current 2017 update assesses whether the 2007
recommendations remain valid. A complete list of
previous recommendations is available at www.asco.
org/hematologic-malignancies-guidelines.
METHODS
Guideline Update Process
ASCO uses a signals2 approach to facilitate
guideline updating. This approach is intended to
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THE BOTTOM LINE
Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice
Guideline Update
Guideline Question
What is the role of BMAs in patients with multiple myeloma?
Target Population
Patients with multiple myeloma.
Target Audience
Medical oncologists, hematologists, radiation oncologists, oncology pharmacists, advanced practice providers, nurses, and other health
care providers.
Methods
A systematic review of the literature was performed, and relevant evidence was evaluated for inclusion in this updated clinical practice
guideline using the signals approach.
Key Recommendations
Indications to initiate a BMA
Patients with lytic disease on plain radiographs or other imaging studies. For patients with multiple myeloma who, on plain
radiograph(s) or other imaging studies (magnetic resonance imaging or computed tomography Scan), have lytic destruction of the
bone or compression fracture of the spine from osteopenia, intravenous pamidronate 90 mg delivered over at least 2 hours or
zoledronic acid 4 mg delivered over at least 15 minutes every 3 to 4 weeks is recommended. Alternative treatment includes the use of
denosumab, a monoclonal antibody that targets receptor activator of nuclear factor kappa-B ligand.
Patients with osteopenia in the absence of lytic disease. Starting bisphosphonates in patients with solitary plasmacytoma or
smoldering (asymptomatic) or indolent myeloma is not recommended.
Adjunct to pain control in patients with pain as a result of osteolytic disease and those receiving other interventions for
fractures or impending fractures. Intravenous pamidronate or zoledronic acid is recommended for patients with pain as a result of
osteolytic disease and as an adjunctive treatment of patients receiving radiation therapy, analgesics, or surgical intervention to stabilize
fractures or impending fractures. Denosumab is an additional option.
Patients with myeloma with normal plain radiograph or osteopenia in bone mineral density measurements. The Expert
Panel supports starting intravenous bisphosphonates in patients with multiple myeloma with osteopenia (osteoporosis), but no
radiographic evidence of lytic bone disease.
Patientswithmonoclonal gammopathy of undetermined significance. Starting bisphosphonates in patients withmonoclonal
gammopathy of undetermined significance is not recommended, unless osteopenia (osteoporosis) exists.
Dosing and selection of BMAs. As a result of increased concerns over renal adverse events, dosing guidelines for patients with
preexisting renal impairment were added to the zoledronic acid package insert. Guidelines recommend that patients with preexisting
mild-to-moderate renal impairment—estimated creatinine clearance, 30 to 60 mL/min—should receive a reduced dosage of
zoledronic acid. No changes in infusion time or interval are required. Zoledronic acid has not been studied in patients with
severe renal impairment and is not recommended for use in these patients. Recent data that compare denosumab with zoledronic acid
has demonstrated fewer adverse events related to renal toxicity with denosumab, and this may be preferred in patients with
compromised renal function.
Pamidronate 90 mg administered over 4 to 6 hours is recommended for patients with extensive bone disease and existing severe
renal impairment—serum creatinine level. 3.0 mg/dL (265 mmol/L) or an estimated creatinine clearance of, 30 mL/min. Although
no dosing guidelines are available for patients with preexisting renal impairment, the Expert Panel recommends that clinicians consider
reducing the initial pamidronate dose in that setting. Infusion times, 2 hours with pamidronate or, 15 minutes with zoledronic acid
should be avoided.
(continued on following page)
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identify new, potentially practice-changing data—signals—that might
translate into revised practice recommendations. The approach relies on
routine searches of the literature and the expertise of ASCO guideline panel
members to identify signals. The Methodology Supplement, available at
www.asco.org/hematologic-malignancies-guidelines, provides additional
information about the signals approach.
PubMed and the Cochrane Library were searched for randomized
controlled trials, systematic reviews, meta-analyses, clinical practice
guidelines, and observational studies for the period from January 2007
through July 2017. The disease and intervention search terms used were
those that were used for the 2007 guideline. An Expert Panel—members
listed in Appendix Table A1, (online only)—was formed in accordance
with the ASCO Conflict of Interest Management Procedures for Clinical
Practice Guidelines, and the panel reviewed the abstracts that were
identified on the basis of predefined signals that would suggest the need to
change a previous recommendation. Additional information about the
results of the updated literature search (Data Supplement 1) and the 2017
search strategy string and results (Data Supplement 2), as well as
THE BOTTOM LINE (CONTINUED)
Duration of therapy. The Expert Panel suggests that bone-targeting treatment continue for a period of up to 2 years. Less-frequent
dosing has been evaluated and should be considered in patients with responsive or stable disease. In patients who do not have active
myeloma and are onmaintenance therapy, the physician may consider a 3-month interval of bisphosphonate administration. There are
no data to support a more precise recommendation for the duration of bisphosphonate therapy in this group of patients. For those
patients for whom bisphosphonates were withdrawn after 2 years, the drug should be resumed upon relapse with new-onset skeletal-
related events. Denosumab should not be stopped abruptly, given its reversible mechanism of action.
Monitoring. The Expert Panel recommends that serum creatinine should be monitored before each dose of pamidronate or
zoledronic acid, in accordance with US Food and Drug Administration (FDA)–approved labeling. Denosumab does not require
monitoring of renal function.
In patients who develop renal deterioration without an apparent cause during bisphosphonate therapy, zoledronic acid or
pamidronate should be withheld. Bisphosphonate therapy can be resumed at the same dosage as that before treatment interruption,
when serum creatinine returns to within 10% of the baseline level. Denosumab requires no dose modification.
Serum calcium should be monitored regularly, and serum vitamin D levels should be evaluated intermittently. Hypocalcemia is an
adverse effect of all bone resorptive agents and is more pronounced with denosumab. Patients should be calcium and vitamin D
repleted.
The Expert Panel also recommends intermittent evaluation—every 3 to 6 months—of all patients receiving pamidronate or
zoledronic acid therapy for the presence of albuminuria on a spot urine sample. In patients who experience unexplained albuminuria,
a 24-hour urine collection should be obtained to assess for. 500 mg/24 hours of urinary albumin, and discontinuation of the drug is
advised until renal problems are resolved. These patients should be reassessed every 3 to 4 weeks—with a 24-hour urine collection for
total protein and urine protein electrophoresis—and pamidronate should be reinstituted over a longer infusion time ($ 4 hours) and
at doses not to exceed 90 mg every 4 weeks when renal function returns to baseline.
The Expert Panel supports the use of screening urinalysis for proteinuria, but underscores that a 24-hour urine collection for the
determination of total protein and electrophoresis is required if the test is positive. Although no similar guidelines are available for
zoledronic acid, some Expert Panel members recommend that zoledronic acid be reinstituted over a longer infusion time ($ 30minutes).
Biochemical markers. Use of the biochemical markers of bone metabolism tomonitor bone-modifying therapy use is not suggested
for routine care.
Osteonecrosis of the jaw. Osteonecrosis of the jaw (ONJ) is an uncommon but potentially serious complication of intravenous
bisphosphonates and denosumab. The Expert Panel agrees with the recommendations described in the revised FDA label for
zoledronic acid and pamidronate, Dear Doctor letters, a white paper, and various position papers or statements. All patients should
receive a comprehensive dental examination and appropriate preventive dentistry before bone-modifying therapy. Active oral
infections should be treated, and sites that are at high risk for infection should be eliminated. While on therapy, patients should
maintain excellent oral hygiene and avoid invasive dental procedures, if possible. Continuation of a bone-targeting agent in the setting
of ONJ has to be individualized and dependent on a risk–benefit ratio and the severity of bone disease.
Additional resources
More information, including a Data Supplement with additional evidence tables, a Methodology Supplement with information about
evidence quality and strength of recommendations, slide sets, and clinical tools and resources, is available at www.asco.org/
hematologic-malignancies-guidelines and www.asco.org/guidelineswiki. Patient information is available at www.cancer.net.
ASCO believes that cancer clinical trials are vital to informmedical decisions and improve cancer care, and that all patients should
have the opportunity to participate.
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a discussion of the ASCO signals approach to guideline updating, are
available at www.asco.org/hematologic-malignancies-guidelines and in the
2017 Data Supplement and 2017 Methodology Supplement, respectively. A
QUOROM diagram of the updated search and the clinical questions are
provided in Data Supplements 3 and 4, respectively.
This systematic review-based guideline product was developed by an
Expert Panel with multidisciplinary representation, including patients, and
by ASCO guidelines staff with health research methodology experience.
The Expert Panel met via teleconference calls to consider the evidence for
each of the 2017 recommendations. The guideline was circulated in draft
form to the Expert Panel. ASCO’s Clinical Practice Guidelines Committee
leadership reviewed and approved the final document. All funding for the
administration of the project was provided by ASCO.
Guideline Disclaimer. The Clinical Practice Guidelines and other
guidance published herein are provided by ASCO to assist providers in
clinical decision making. The information herein should not be relied
upon as being complete or accurate, nor should it be considered as in-
clusive of all proper treatments or methods of care or as a statement of the
standard of care. With the rapid development of scientific knowledge, new
evidence may emerge between the time information is developed and when
it is published or read. The information is not continually updated andmay
not reflect the most recent evidence. The information addresses only
the topics specifically identified therein and is not applicable to other
interventions, diseases, or stages of diseases. This information does not
mandate any particular course of medical care. Furthermore, the in-
formation is not intended to substitute for the independent professional
judgment of the treating provider, as the information does not account
for individual variation among patients. Recommendations reflect high,
moderate, or low confidence that the recommendation reflects the net
effect of a given course of action. The use of words like “must,” “must not,”
“should,” and “should not” indicates that a course of action is recommended
or not recommended for either most or many patients, but there is latitude
for the treating physician to select other courses of action in individual cases.
In all cases, the selected course of action should be considered by the treating
provider in the context of treating the individual patient. Use of the in-
formation is voluntary. ASCO provides this information on an “as is” basis
and makes no warranty, express or implied, regarding the information.
ASCO specifically disclaims any warranties of merchantability or fitness for
a particular use or purpose. ASCO assumes no responsibility for any injury
or damage to persons or property arising out of or related to any use of this
information, or for any errors or omissions.
This is the most recent information as of the publication date. For the
most recent information, and to submit new evidence, please visit www.
asco.org/hematologic-malignancies-guidelines and the ASCO Guidelines
Wiki (www.asco.org/guidelineswiki).
Guideline and Conflicts of Interest. The Expert Panel was assembled in
accordance with ASCO’s Conflict of Interest Policy Implementation for
Clinical Practice Guidelines (“Policy,” found at http://www.asco.org/rwc). All
members of the Expert Panel completed ASCO’s disclosure form, which
requires disclosure of financial and other interests, including relationships
with commercial entities that are reasonably likely to experience direct
regulatory or commercial impact as a result of promulgation of the
guideline. Categories for disclosure include employment; leadership; stock
or other ownership; honoraria, consulting or advisory role; speaker’s bureau;
research funding; patents, royalties, other intellectual property; expert
testimony; travel, accommodations, expenses; and other relationships. In
accordance with the Policy, the majority of the members of the Expert Panel
did not disclose any relationships constituting a conflict under the Policy.
RESULTS
The search yielded 35 publications.3-37 After careful review of the
identified publications, the Expert Panel concluded that additional
BMAs are now available, and the 2007 guideline recommendations1
have been updated. The guideline recommendations also provide
information to additionally clarify the evidence that supports ad-
ditional recommendations on duration and complications of BMAs.
A bibliography and summary of the results of the updated literature
search is provided in Data Supplement 2.
RECOMMENDATIONS
The 2017 recommendations are listed in the Bottom Line Box. These
recommendations are consistent with the previous recommenda-
tions, with new information on denosumab, a receptor activator of
nuclear factor kappa-B ligand inhibitor.36 Additional modifications
were made to some of the recommendations on the basis of recent
data to better clarify the indications for treatment, duration of
treatment, and associated complications of treatment, and these are
discussed in greater depth in this section.
The definition of active multiple myeloma that requires therapy
has been revised. Hypercalcemia, renal dysfunction, anemia, or bone
disease remain indications for treatment. In the absence of these
features, patients who have . 60% bone marrow plasma cells, in-
volved free light chain. 100mg/Lwith k/l ratio. 100-fold, ormore
than one site of bone disease on magnetic resonance imaging or on
positron emission tomography computed tomography scanning are
now recommended for treatment. Any patient who receives treatment
for active multiple myeloma should receive bisphosphonate therapy.
In a large randomized trial that was conducted in theUnited Kingdom
(MRC IX Trial), patients without lytic bone disease also benefitted
from bisphosphonate therapy (zoledronic acid) with reduced skeletal-
related events at the time of relapse, and there was improvement in
progression-free survival, but not overall survival.20,21 Clodronate is
approved worldwide, except in the United States, for either oral or
intravenous administration; however, the recent MRC IX randomized
controlled trial demonstrates that intravenous zoledronic acid is
superior for avoiding skeletal complications.20,21
Patients With Lytic Disease on Plain Radiographs or
Other Imaging Studies
The previous guidelines recommended the use of intravenous
bisphosphonates for patients with myeloma with evidence of bone
disease.1 Denosumab was studied in a large, international, ran-
domized, double-blinded, phase III study that evaluated the ef-
ficacy and safety of denosumab compared with zoledronic acid for
the prevention of skeletal-related events in patients with newly
diagnosed multiple myeloma.36,37 Patients (N = 1,718) were ran-
domly assigned in a 1:1 allocation ratio to denosumab 120 mg
subcutaneously every 4 weeks or zoledronic acid 4 mg intravenously
every 4 weeks. Denosumab was noninferior to zoledronic acid in
delaying the time to first skeletal-related events. Overall survival for
patients who were treated with denosumab was not different than
patients whowere treated with zoledronic acid. Fewer adverse events
related to renal toxicity were reported with denosumab, providing an
additional option as a BMA in multiple myeloma.
Denosumab is more expensive than zoledronic acid or
pamidronate and must be considered in treatment decisions.
Table 1 provides an overview of the estimated cost of these
medications in the United States.
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Duration and Frequency of Therapy
The risk of ONJ has prompted the use of less-frequent dosing of
zoledronic acid, which may be an option for patients.26,38 These two
studies were carried out to address the dosing of zoledronic acid every
3 months. To this end, the Z-MARK study evaluated whether patients
with 1 to 2 years of prior intravenous bisphosphonate therapy could
be treated safely long term with less-frequent zoledronic acid on the
basis of markers of bone turnover.26 Patients with urinary N-telo-
peptide of type I collagen (uNTX) levels, 50 nmol/mmol creatinine
received zoledronate 4 mg every 12 weeks versus every 4 weeks for
higher levels of uNTX. uNTX levels weremonitored over the course of
treatment, and the dosing of zoledronic acid was adjusted as a result.
In addition, patients who developed a skeletal-related event or who
experienced disease progression were treated on the every-4-week
schedule thereafter, regardless of uNTX levels. Themajority of patients
(79 of 121) received the every-12-week schedule throughout the study.
Of the 79 patients, only seven patients (8.9%) had a skeletal-related
event in year 1 and five in year 2. The low incidence of skeletal-related
events overall in this study compared with prior studies with zole-
dronic acid suggests that less-frequent dosing of zoledronic acid
beyond 1 to 2 years may continue to reduce the risk of skeletal-related
events. Furthermore, it also suggests more effective treatment of
multiple myeloma with novel therapies may have protective effects on
the bone.
In another large randomized trial, zoledronic acid that was
administered every 12 weeks was compared with that administered
every 4 weeks to demonstrate noninferiority.38 This randomized,
open-label clinical trial included 1,822 patients with at least one site
of bone involvement for a treatment duration of 2 years. Two
hundred seventy-two patients in this trial had multiple myeloma.
The proportions of skeletal-related events did not differ significantly
between the every-4-week dosing group versus the every-12-week
dosing group. Among other end points, there was no difference
noted in the incidence of ONJ and kidney dysfunction. At the time of
relapse, retreatment on the 4-week schedule is recommended.
Although both these studies have used less-frequent dosing,
there are several limitations that should be kept in mind. The
Z-MARK study was a single-arm study with only 121 patients
included; however, this trial did address patients who received up
to 4 years of bisphosphonate treatment. In contrast, the trial by
Himmelstein et al was randomized, but only included 272 patients
with myeloma. Moreover, in this open-label trial, nearly 40% of
patients did not complete the stipulated 2-year duration of the
study. Finally, this trial did not address the duration of therapy
beyond 2 years. Given these caveats, the guidelines committee has
only made these as suggested recommendations.
ONJ
ONJ is a major complication that is increasingly observed when
more potent bisphosphonates, such as pamidronate and zoledronic
acid, have been used. Although first described with bisphosphonates,
ONJ also occurs with denosumab. The Expert Panel agrees with the
recommendations described in the revised FDA label for zoledronic
acid and pamidronate, Dear Doctor letters, awhite paper, and various
position papers or statements. All patients with cancer should receive
a comprehensive dental examination and appropriate preventive
dentistry before bone-modifying therapy. Active oral infections
should be treated, and sites that are at high risk for infection should
be eliminated. While on therapy, patients should maintain excellent
oral hygiene and avoid invasive dental procedures, if possible.
Continuation of a bone-targeting agent in the setting of ONJ has to be
individualized and dependent on a risk–benefit ratio and the severity
of bone disease. Other notable complications of BMAs include
atypical fractures of the femur.19
ASCO believes that cancer clinical trials are vital to inform
medical decisions and improve cancer care, and that all patients
should have the opportunity to participate.
ADDITIONAL RESOURCES
More information, including Data andMethodology Supplements,
slide sets, and clinical tools and resources, is available at www.asco.
Table 1. Estimated Prices for Bone-Modifying Agents in the United States
Agent (route) Dose (mg) Schedule
Price Per Dose
(US dollars)
Total Price Per 1-Year Treatment Cycle
(US dollars)
Bisphosphonate
Pamidronate
(intravenous)
90 Delivered over no less than 2 hours every
3 or 4 weeks
$30.67* Every-4-weeks price: $398.71 ($30.67 3 13)
Zoledronic acid
(intravenous)
4 Delivered over no less than 15 minutes
every 12 weeks or every 3-4 weeks
$53.64† Every-12-weeks price: $214.56 ($53.64 3 4)
Every-4-weeks price: $697.37 ($53.64 3 13)
Monoclonal antibody
Denosumab
(subcutaneous
injection)
120 Every 4 weeks $1,995.48‡ Every-4-weeks price: $25,941.24 ($1,995.48 3 13)
NOTE. Prices per dose were for a single infusion or per single injection. Prices for drugs reimbursed through Medicare Part B only were identified from the second
quarter 2017 Medicare Payment Allowable Part B Drugs Average Sales Price data.39 Drug price may vary by plan and by pharmacy where a medication is filled (eg,
preferred or nonpreferred pharmacies). Drug prices are dynamic, and thus the prices listed in the table may not reflect current prices. Bone-modifying treatment continue
for a period of up to 2 years. Less-frequent dosing has been evaluated and should be considered in patients with responsive or stable disease. Continuous use is at the
discretion of the treating physician and the risk of ongoing skeletal morbidity. Retreatment should be initiated at the time of disease relapse. While on therapy, patients
should maintain excellent oral hygiene and avoid invasive dental procedures.
*$10.223/30 mg 3 3.
†$13.411/1 mg 3 4.
‡$16.629/1 mg 3 120.
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org/hematologic-malignancies-guidelines. Patient information is
available at www.cancer.net. Visit www.asco.org/guidelineswiki to
provide comments on the guideline or to submit new evidence.
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